Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006355 · ClinicalTrials.gov registry record · Phase 1
Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006355: Completed Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00006355 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006355, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of pyrazoloacridine followed by radiation therapy in treating adults who have newly diagnosed supratentorial glioblastoma multiforme.
Interventions
- RADIATION radiation therapy
- PROCEDURE adjuvant therapy
- DRUG pyrazoloacridine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00006355 record still lists
NCT00006355 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which radiation therapy is the first listed.
NCT00006355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006355 about?
NCT00006355 is a clinical study titled "Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the eff...
What is the current status of trial NCT00006355?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00006355?
The interventions under investigation include: radiation therapy (RADIATION), adjuvant therapy (PROCEDURE), pyrazoloacridine (DRUG).
Who is sponsoring clinical trial NCT00006355?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia